FRA
ONC

Front Row Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Front Row Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18
Closed -$2.57K – 862
2024
Q2 		$2.57K Sell
18
-1
-5% -$154 ﹤0.01% 826
2024
Q1 		$2.97K Buy
+19
New +$3.06K ﹤0.01% 799
2023
Q4 		– Sell
-9
Closed -$1.62K – 829
2023
Q3 		$1.62K Sell
9
-3
-25% -$594 ﹤0.01% 831
2023
Q2 		$2K Hold
12
– – ﹤0.01% 832
2023
Q1 		$3K Sell
12
-1
-8% -$240 ﹤0.01% 791
2022
Q4 		$3K Sell
13
-2
-13% -$367 ﹤0.01% 756
2022
Q3 		$2K Sell
15
-2
-12% -$343 ﹤0.01% 845
2022
Q2 		$3K Sell
17
-3
-15% -$469 ﹤0.01% 780
2022
Q1 		$4K Hold
20
– – ﹤0.01% 778
2021
Q4 		$5K Hold
20
– – ﹤0.01% 763
2021
Q3 		$7K Sell
20
-3
-13% -$981 ﹤0.01% 674
2021
Q2 		$6K Buy
23
+4
+21% +$1.32K ﹤0.01% 717
2021
Q1 		$7K Hold
19
– – ﹤0.01% 656
2020
Q4 		$5K Sell
19
-1
-5% -$275 ﹤0.01% 702
2020
Q3 		$6K Buy
+20
New +$4.7K ﹤0.01% 661

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Front Row Advisors's ONC Position: Q3 2024 in Review

Front Row Advisors sold out of BeOne Medicines Ltd (ONC) in Q3 2024, closing a stake of 18 shares — an estimated $2.57K sold.

Front Row Advisors first reported a position in ONC in Q3 2020 and held it in 15 quarters. The position peaked at $7K in Q3 2021. 228 funds tracked by Wall St. Rank hold ONC as of Q3 2024.

  • Front Row Advisors reported no remaining BeOne Medicines Ltd position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 18 BeOne Medicines Ltd shares in Q3 2024, an estimated $2.57K.
  • Front Row Advisors first reported a position in BeOne Medicines Ltd in Q3 2020 and held it in 15 quarters.
  • Front Row Advisors's BeOne Medicines Ltd position peaked at $7K in Q3 2021.
  • 228 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.